Clinical trials
Autoimmune Diseases trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 7 |
| Terminated | 3 |
| Active, not recruiting | 1 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brigham and Women's Hospital | 3 |
| University of Pittsburgh | 2 |
| University of Texas at Austin | 2 |
| Ageless Regenerative Institute | 1 |
| Cytokind, Inc. | 1 |
| Elliot Lander | 1 |
| Emory University | 1 |
| Fuller Research Foundation | 1 |
| Healeon Medical Inc | 1 |
| Jaeb Center for Health Research | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Autoimmune Diseases | 29 |
| Multiple Sclerosis | 9 |
| Immune System Diseases | 6 |
| Arthritis, Rheumatoid | 5 |
| Demyelinating Diseases | 5 |
| Endocrine System Diseases | 5 |
| Autoimmune Diseases of the Nervous System | 4 |
| Diabetes Mellitus | 4 |
| Diabetes Mellitus, Type 1 | 4 |
| Glucose Metabolism Disorders | 4 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.